The recent studies on selective inhibition of COX-2 caused suppression of inflammation and azoxymethane-induced colon cancer have shown the importance of COX-2 as a target for anti-inflammatory and anticancer therapy (Dannhardt and Kiefer, [2001]; Subhashini et al. [2004]; Amaravani et al. [2006]). The gene discussed is PTGS2; the disease is malignant colon neoplasm.